Cell Reports (Dec 2023)

A mitochondrial inside-out iron-calcium signal reveals drug targets for Parkinson’s disease

  • Vinita Bharat,
  • Aarooran S. Durairaj,
  • Roeland Vanhauwaert,
  • Li Li,
  • Colin M. Muir,
  • Sujyoti Chandra,
  • Chulhwan S. Kwak,
  • Yann Le Guen,
  • Pawan Nandakishore,
  • Chung-Han Hsieh,
  • Stefano E. Rensi,
  • Russ B. Altman,
  • Michael D. Greicius,
  • Liang Feng,
  • Xinnan Wang

Journal volume & issue
Vol. 42, no. 12
p. 113544

Abstract

Read online

Summary: Dysregulated iron or Ca2+ homeostasis has been reported in Parkinson’s disease (PD) models. Here, we discover a connection between these two metals at the mitochondria. Elevation of iron levels causes inward mitochondrial Ca2+ overflow, through an interaction of Fe2+ with mitochondrial calcium uniporter (MCU). In PD neurons, iron accumulation-triggered Ca2+ influx across the mitochondrial surface leads to spatially confined Ca2+ elevation at the outer mitochondrial membrane, which is subsequently sensed by Miro1, a Ca2+-binding protein. A Miro1 blood test distinguishes PD patients from controls and responds to drug treatment. Miro1-based drug screens in PD cells discover Food and Drug Administration-approved T-type Ca2+-channel blockers. Human genetic analysis reveals enrichment of rare variants in T-type Ca2+-channel subtypes associated with PD status. Our results identify a molecular mechanism in PD pathophysiology and drug targets and candidates coupled with a convenient stratification method.

Keywords